Compare CRAI & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRAI | SVRA |
|---|---|---|
| Founded | 1965 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 1998 | 2009 |
| Metric | CRAI | SVRA |
|---|---|---|
| Price | $165.22 | $5.07 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $245.00 | $7.33 |
| AVG Volume (30 Days) | 89.6K | ★ 1.4M |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.48% | N/A |
| EPS Growth | ★ 20.77 | N/A |
| EPS | ★ 8.14 | N/A |
| Revenue | ★ $751,583,000.00 | N/A |
| Revenue This Year | $7.82 | N/A |
| Revenue Next Year | $5.14 | $430.87 |
| P/E Ratio | $19.91 | ★ N/A |
| Revenue Growth | ★ 9.33 | N/A |
| 52 Week Low | $132.17 | $3.34 |
| 52 Week High | $227.29 | $7.01 |
| Indicator | CRAI | SVRA |
|---|---|---|
| Relative Strength Index (RSI) | 44.75 | 44.35 |
| Support Level | $152.37 | $4.77 |
| Resistance Level | $166.99 | $5.48 |
| Average True Range (ATR) | 5.22 | 0.22 |
| MACD | -0.30 | -0.02 |
| Stochastic Oscillator | 46.90 | 40.14 |
CRA International Inc is a consulting firm specializing in providing economic, financial and management consulting services. The company provides advisory services on economic and financial matters related to litigation and regulatory proceedings, and advises corporations on business and performance-related matters. Its consulting services are organized into two areas: litigation, regulatory and financial consulting, and management consulting. The company's clients include domestic and foreign companies, government agencies, public and private utilities, and national and international trade associations. It derives revenues by providing professional and consulting services. Geographically, the maximum revenue is derived from the United States, followed by United Kingdom and other regions.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).